N,N'-二环己基碳二亚胺 | 538-75-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他保护氨基酸
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N,N'-二环己基碳二亚胺
• 中文别名: 二环己基碳二亚胺；二环己；N,N'-二环己基碳酰亚胺；N,N’-二环己基碳酰亚胺；N，N-二环己基碳二亚胺；N,N'-二环已基碳酰亚胺；N,N-二环己基羰二亚胺；N,N-二环己基碳二亚胺；N,N-二环己基碳酰亚胺；DCC；N,N'-二环已基碳二亚胺
• 英文名称: dicyclohexyl-carbodiimide
• 英文别名: 1,3-Dicyclohexylcarbodiimide；dicyclohexylcarbodiimid；DCCD；dcc；N,N'-dicyclohexyl-carbodiimide；N,N′-dicyclohexyl-carbodiimide；N,N’-dicyclohexyl carbodiimide；dicyclohexylmethanediimine；N,N’-methanediylidenedicyclohexanamine；N,N'-methanediylidenedicyclohexanamine；N,N'-dicyclohexylmethanediimine；Dicyclohexylcarbodiimide
• CAS: 538-75-0
• 化学式: C₁₃H₂₂N₂
• mdl: MFCD00011659
• 分子量: 206.331
• InChiKey: QOSSAOTZNIDXMA-UHFFFAOYSA-N

物化性质

• 熔点：
  34-35 °C(lit.)
• 沸点：
  122-124 °C6 mm Hg(lit.)
• 密度：
  1.247 g/mL at 25 °C
• 闪点：
  190 °F
• 溶解度：
  在二氯甲烷中可溶0.1 g/mL，澄清，无色
• LogP：
  5.567-6.83 at 25℃
• 物理描述：
  N,n'-dicyclohexylcarbodiimide is a white crystalline solid with a heavy sweet odor. (NTP, 1992)
• 颜色/状态：
  Crystalline mass
• 气味：
  Heavy sweet odor
• 蒸汽压力：
  3.39X10-3 mm Hg at 25 °C (est)
• 分解：
  When heated to decomposition it emits toxic vapors of /oxides of nitrogen/.
• 腐蚀性：
  Corrosive to tissue
• 稳定性/保质期：
  1. 按照规格使用和贮存，不会发生分解，避免与氧化物接触。 2. 皮肤对这种试剂具有较强的刺激性，操作时需戴上橡胶手套，并应在通风橱中进行。该试剂容易吸潮，应保存在干燥器中。

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.923
• 拓扑面积：
  24.7
• 氢给体数：
  0
• 氢受体数：
  2

ADMET

毒理性

• 副作用

神经毒素 - 其他中枢神经系统神经毒素

Neurotoxin - Other CNS neurotoxin

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 毒性数据

大鼠LC50 = 159 mg/m³/6小时

LC50 (rat) = 159 mg/m3/6h

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、袋阀面罩装置或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者身体前倾或置于左侧（如果可能的话，头部向下）以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗帮助。 /刺激物材料/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand-valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR as necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Irritating materials/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。鼓励患者深呼吸。观察呼吸不足的迹象，如有必要，协助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克并治疗，如有必要……。预见并治疗癫痫发作，如有必要……。对于眼睛污染，立即用水冲洗眼睛。在转运过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的呕吐反射且不流口水，则用水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。/刺激物材料/

/SRP:/ Basic Treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Encourage patient to take deep breaths. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . /Irritating materials/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。在上呼吸道阻塞的初期迹象出现时，可能需要尽早进行插管。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……监测心率和必要时治疗心律失常……开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸钠林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……用地西泮或劳拉西泮治疗癫痫……使用丙美卡因氢氯化物协助眼部冲洗……/刺激性材料/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Early intubation at the first sign of upper airway obstruction may be necessary. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Monitor cardiac rhythm and treat arrhythmias if necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... .Treat seizures with diazepam or lorazepam ... Use proparacaine hydrochloride to assist eye irrigation ... . /Irritating materials/

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• TSCA：
  Yes
• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S16,S24,S24/25,S26,S36,S36/37/39,S37/39,S41,S45,S53
• 危险类别码：
  R36/38,R41,R21,R43
• WGK Germany：
  3
• 海关编码：
  29252000
• 危险品运输编号：
  UN 2922 8/PG 2
• 危险类别：
  6.1
• RTECS号：
  FF2160000
• 包装等级：
  II
• 危险标志：
  GHS05,GHS06,GHS08
• 危险性描述：
  H302,H311,H317,H318,H351
• 危险性防范说明：
  P280,P301 + P312 + P330,P302 + P352 + P312,P305 + P351 + P338 + P310
• 储存条件：
  储存于阴凉、干燥和通风良好的库房中，远离火种和热源，并防止阳光直射。包装需密封保存，并与酸类及食用化学品分开存放，严禁混合储存。储区应配备适当的材料以处理可能的泄漏。

SDS

Name:	Dicyclohexylcarbodi-imide Material Safety Data Sheet
Synonym:	DCC; N,N'-Methanetetraylbiscyclohexanamine
CAS:	538-75-0

Section 1 - Chemical Product MSDS Name:Dicyclohexylcarbodi-imide Material Safety Data Sheet
Synonym:DCC; N,N'-Methanetetraylbiscyclohexanamine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
538-75-0	Dicyclohexylcarbodiimide	100.0	208-704-1

Hazard Symbols: T
Risk Phrases: 22 24 41 43

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Toxic in contact with skin. Risk of serious damage to eyes. May cause sensitization by skin contact.Moisture sensitive.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes severe eye irritation.
Skin:
Causes moderate skin irritation.
Ingestion:
The toxicological properties of this substance have not been fully investigated.
Inhalation:
The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 538-75-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 122-124 deg C
Freezing/Melting Point: 34-35 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Reacts with water.
Specific Gravity/Density: Not available.
Molecular Formula: C13H22N2
Molecular Weight: 206.1674

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, ignition sources, exposure to moist air or water.
Incompatibilities with Other Materials:
Acids, strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 538-75-0: FF2160000 LD50/LC50:
CAS# 538-75-0: Dermal, guinea pig: LD50 = 10 mL/kg; Inhalation, rat: LC50 = 159 mg/m3/6H; Oral, mouse: LD50 = >800 mg/kg; Oral, rat: LD50 = 400 mg/kg.
Rat: LC50 = 0.159-0.417 Carcinogenicity:
Dicyclohexylcarbodiimide - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T
Risk Phrases:
R 22 Harmful if swallowed.
R 24 Toxic in contact with skin.
R 41 Risk of serious damage to eyes.
R 43 May cause sensitization by skin contact.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28 After contact with skin, wash immediately
with...
WGK (Water Danger/Protection)
CAS# 538-75-0: 2
Canada
CAS# 538-75-0 is listed on Canada's DSL List.
CAS# 538-75-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 538-75-0 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

二环己基碳二亚胺(DCC)简介

二环己基碳二亚胺（DCC）也用于阿米卡星及氨基酸的合成脱水，是一种很好的低温生化脱水剂，同样适用于酸、酐、醛、酮等物质的合成。在日本，它广泛用作谷胱甘肽的脱水剂，占总消费量的90%。作为脱水缩合剂时，该品可在常温下经短时间反应生成二环己基脲。

应用

应用领域

• 二环己基碳二亚胺（DCC）是一种优异的多肽缩合剂，在多肽、核酸及丁胺卡那霉素合成中广泛应用。

• 在阿米卡星和氨基酸的合成脱水中表现出色，是低温生化脱水的理想选择。

急救措施

急救建议

• 吸入：将患者移至新鲜空气处。
• 皮肤接触：脱去污染衣物，并用肥皂水和清水彻底冲洗皮肤；如有不适，请就医。
• 眼睛接触：分开眼睑，用流动清水或生理盐水冲洗眼睛；立即就医。
• 食入：立即漱口，禁止催吐；立即就医。

化学性质

物理性质

二环己基碳二亚胺（DCC）为白色结晶或微黄色透明液体。熔点35-36℃，沸点154-156℃（1.47kPa），98-100℃（66.7kPa）。溶于苯、乙醇和乙醚，不溶于水。

应用

• 作为脱水缩合剂时，可在常温下迅速反应生成二环己基脲。
• 反应产物在有机溶剂中溶解度小，易于分离；即使在水溶液中也能进行反应。
• 在室温条件下，能够由具有游离羧基的化合物和具有游离氨基的化合物合成肽，并且收率很高。

用途

• 生化试剂及有机合成脱水缩合剂
• 主要用于阿米卡星及氨基酸的合成脱水
• 多肽人工合成中氨基酸的缩合，如Fmoc固相合成中的应用
• 偶联试剂、脱水试剂，修饰牛心脏线粒体转氢酶等

生产方法

1. 二环己基硫脲法：工业上由环己胺与二硫化碳反应生成N,N'-二环己基硫脲，再经脱硫化氢而得。
2. 二环己胺尿素法：也可由N,N'-二环己基脲与五氧化二磷在吡啶中反应制备。

反应信息

• 作为反应物：
  描述：

  N,N'-二环己基碳二亚胺 在 copper (I) iodide 作用下， 反应 24.0h， 生成 N-甲基环己胺
  参考文献：
  名称：

  在碳二亚胺促进的温和条件下，由脂肪醇和二氧化碳形成有机碳酸盐的机理。DFT计算与实验研究

  摘要：

  二环己基（CYN Ç NCY，DCC）促进在温度低至310 K和CO的中等压力容易形成从脂族醇与二氧化碳有机碳酸酯2（0.1兆帕）以可接受的速率。DCC的转化率是定量的，在330 K下，该反应对碳酸盐的选择性很高。升高温度可提高转化率，但会降低选择性。一项详细的研究使我们能够分离或鉴定在有或没有二氧化碳的情况下，醇与DCC反应形成的中间体。第一步是将醇添加到异丙苯中（已知反应）并形成O-烷基异脲[RHNC（OR'）NR]，其可以通过H键与第二个醇分子相互作用（到目前为止尚未描述过该反应）。这样的加合物可以通过NMR检测。在醇中，不存在CO 2时，会转化为氨基甲酸酯和仲胺，而在存在CO 2时，碳酸二烷基酯（RO）2 CO与尿素[CyHN-CO-NHCy]一起形成。已经用各种脂族醇如甲醇，乙醇和烯丙醇测试了该反应。尤其是，这是合成碳酸二烯丙酯的便利途径。O-甲基-N，N'-二环己基异脲也可在CO

  DOI：

  10.1021/jo050392y
• 作为产物：
  描述：

  N,N'-Dicyclohexyl-chlorformamidin 在 sodium hydroxide 作用下， 以 水 为溶剂， 以92.4%的产率得到N,N'-二环己基碳二亚胺
  参考文献：
  名称：

  一种利用vilsmeier试剂制备二环己基碳二亚胺的方法

  摘要：

  本发明公开了一种利用vilsmeier试剂制备二环己基碳二亚胺的方法，利用N,N‑二甲基甲酰胺(DMF)和氯化亚砜(SOCl2)制得vilsmeier试剂与二环己基脲(DCU)反应，经过后处理后得到二环己基碳二亚胺。该方法采用了vilsmeier试剂，能够在较温和的条件下进行反应，工艺安全稳定，适合工业化大规模生产。

  公开号：

  CN112079748A
• 作为试剂：
  描述：

  1-(4-azido-2,5-dideoxy-2-fluoro-5-iodo-β-D-arabino-furanosyl)uracil 在 吡啶 、 dipotassium hydrogenphosphate 、 氨 、 四丁基硫酸氢铵 、 potassium diazodicarboxylate 、 sodium hydride 、 溶剂黄146 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 反应 23.17h， 生成
  参考文献：
  名称：

  一种新型的核苷酸衍生物及其药物组合物和用途

  摘要：

  本发明公开了一种新型的核苷酸类衍生物及其药物组合物和用途，所述核苷酸类衍生物如式(I)所示；该类衍生物可用于制备抗病毒感染的药物。#imgabs0#

  公开号：

  CN117486958A

文献信息

• SYNTHESIS OF CYCLIC AMIDINES
  申请人：Lentzen George

  公开号：US20110178292A1

  公开（公告）日：2011-07-21

  The invention relates to an innovative method for synthesis of cyclic amidines. The synthesis starts from a β-, γ- or δ-lactone which is twofold brominated. After esterification of the carboxyl function, the bromine atoms are nucleophilically substituted and the corresponding diamino compound is obtained. The ring closure to the cyclic amidine is accomplished subsequently by reaction with orthoester, imidate or thioimidate. Owing to interposing additional steps for recovery of the diamino compound in enantiomerically pure form, the enantiomers of the cyclic amidines can be stereoselectively synthesized.

  该发明涉及一种合成环氨基甲酸盐的创新方法。合成从β-、γ-或δ-内酯开始，该内酯经过双溴化。在羧基酯化后，溴原子被亲核取代，得到相应的二氨基化合物。随后通过与正酯、亚胺酯或硫代亚胺的反应实现环氨基甲酸盐的环闭合。由于插入额外步骤以以对映纯形式回收二氨基化合物，因此可以立体选择性地合成环氨基甲酸盐的对映体。
• [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
  申请人：MERCK & CO INC

  公开号：WO2009152025A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• [EN] PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILES COMME INHIBITEURS DE FAAH
  申请人：MERCK & CO INC

  公开号：WO2009151991A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide
  申请人：Archimica GmbH

  公开号：EP2399901A1

  公开（公告）日：2011-12-28

  The invention relates to R)-1-Benzylcarbamoyl-2-hydroxy-ethyl)-carbamic acid tert-butyl ester (compound III) with an ee of greater than 90%. and a process for producing the same

  这项发明涉及具有大于90%的ee的(R)-1-苄基氨甲酰-2-羟基乙基)-氨甲酸叔丁酯（化合物III）以及生产该化合物的方法
• Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
  申请人：Abbott Laboratories

  公开号：US20040116518A1

  公开（公告）日：2004-06-17

  The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及新型肉桂酰胺化合物，用于治疗炎症和免疫性疾病以及脑血管痉挛，以及含有这些化合物的药物组合物，以及在哺乳动物中抑制炎症或抑制免疫反应的方法。

表征谱图